BioPharma Resources

Drug Trial Radar · NCT07258979

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

A Multicenter, Open-label, Phase Ib/II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 Combined With Toripalimab, With or Without Cisplatin, in Subjects With Recurrent or Metastatic Nasopharyngeal Carcinoma.

Last checked: Nov 19, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 202 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

202

Planned (sponsor's estimate)

Start

Nov 5, 2025

Primary completion

Feb 2028

Study completion May 2028

Sponsor

Sponsor type
Industry
First posted
Dec 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, Phase Ib/II study conducted in China to evaluate the safety, efficacy, and pharmacokinetic (PK) characteristics of YL201 combined with Toripalimab (doublet regimen) or YL201 combined with Toripalimab and Cisplatin (triplet regimen) in subjects with recurrent or metastatic nasopharyngeal carcinoma.

Conditions

  • Recurrent or Metastatic Nasopharyngeal Carcinoma

Interventions

  • YL201Drug

    YL201 will be administered as an IV infusion

  • ToripalimabDrug

    Toripalimab will be administered as an IV infusion

  • CisplatinDrug

    Cisplatin will be administered as an IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Dose-limiting toxicities (DLTs)Time frame: Approximately within 36 months
  2. Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Time frame: Approximately within 36 months
  3. Progression-Free Survival (PFS) as assessed by RECIST v1.1Time frame: Approximately within 36 months

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China · Not yet recruiting

  • Zhangzhou Municiple Hospital of Fujian Province

    Zhangzhou, Fujian, China · Not yet recruiting

  • Dongguan People's Hospital

    Dongguan, Guangdong, China · Not yet recruiting

  • Affiliated Cancer Hospital and Institute of Guangzhou Medical University

    Guangzhou, Guangdong, China · Not yet recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • The First Affiliated Hospital of Guangdong Pharmaceutical University

    Guangzhou, Guangdong, China · Not yet recruiting

  • Jiangmen Central Hospital

    Jiangmen, Guangdong, China · Not yet recruiting

  • Yuebei People's Hospital

    Shaoguan, Guangdong, China · Not yet recruiting

  • The Second Affiliated Hospital of Guilin Medical University

    Guilin, Guangxi, China · Not yet recruiting

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China · Not yet recruiting

  • The First Affiliated Hospital of Hainan Medical University

    Haikou, Hainan, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Not yet recruiting

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, China · Not yet recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Not yet recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China · Not yet recruiting

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China · Not yet recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.